Amgen has underperformed the Nasdaq over the past year, but analysts are still fairly bullish about the biopharma stock's ...

When you buy and hold a stock for the long term, you definitely want it to provide a positive return. But more ...

Amgen (NASDAQ: AMGN) has outperformed the market over the past 15 years by 1.0% on an annualized basis producing an average annual return of 13.12%. Currently, Amgen has a market capitalization of ...

Truist assumed coverage of Amgen (AMGN) with a Hold rating with a price target of $318, up from $298. The firm views the ...

As of Wednesday, November 26, Arrowhead Pharmaceuticals, Inc.’s ARWR share price has surged by 9.30%, which has investors ...

Amgen (AMGN) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

In addition to Scotiabank, Amgen also received a Buy from Piper Sandler’s David Amsellem in a report issued yesterday. However, on the same day, Truist Financial maintained a Hold rating on Amgen ...

Detailed price information for Biomarin Pharmaceuticals (BMRN-Q) from The Globe and Mail including charting and trades.

The milestone was earned when Arrowhead achieved the second development milestone event in a Phase 1/2 clinical study of ...

The price cuts through the U.S. Medicare health plan for Americans age 65 and older come as President Donald Trump’s ...

Discover why Ideaya Biosciences, Inc. is rated a Buy for its promising oncology pipeline and upcoming catalysts. Click for my ...

Health care stocks have lagged the S&P 500 in 2025 thanks in part to U.S. policy uncertainty. However, health care stocks can often be a solid defensive play in an uncertain economy. People don' ...